Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,306,607
  • Shares Outstanding, K 53,825
  • Annual Sales, $ 73,990 K
  • Annual Income, $ -124,860 K
  • 60-Month Beta 0.77
  • Price/Sales 72.08
  • Price/Cash Flow N/A
  • Price/Book 12.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.72
  • Number of Estimates 7
  • High Estimate -0.15
  • Low Estimate -1.04
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -111.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.32 +19.55%
on 05/01/20
108.50 -5.99%
on 05/12/20
+2.50 (+2.51%)
since 04/24/20
3-Month
66.44 +53.52%
on 03/17/20
108.50 -5.99%
on 05/12/20
+14.64 (+16.76%)
since 02/26/20
52-Week
37.01 +175.60%
on 06/11/19
108.50 -5.99%
on 05/12/20
+59.94 (+142.51%)
since 05/24/19

Most Recent Stories

More News
Acceleron Announces Presentations on REBLOZYL(R) (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...

XLRN : 101.67 (+3.12%)
Acceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Session on June 24, 2020

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...

XLRN : 101.67 (+3.12%)
Acceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercept's Potential as a Novel Therapy in Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...

XLRN : 101.67 (+3.12%)
Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss

Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.

INCY : 99.48 (+0.11%)
NVS : 85.33 (+0.49%)
BMY : 60.49 (-0.49%)
XLRN : 101.67 (+3.12%)
Acceleron Pharma (XLRN) Reports Q1 Loss, Lags Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of -13.10% and -21.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

XLRN : 101.67 (+3.12%)
Acceleron: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Monday reported a loss of $50.9 million in its first quarter.

XLRN : 101.67 (+3.12%)
Acceleron Reports First Quarter 2020 Operating and Financial Results

--- REBLOZYL received positive CHMP opinion for the treatment of adults with transfusion-dependent anemia in lower-risk MDS and beta-thalassemia -

XLRN : 101.67 (+3.12%)
Acceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results....

XLRN : 101.67 (+3.12%)
Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension

--PRIME designation comes just three weeks after US FDA granted sotatercept Breakthrough Therapy designation

XLRN : 101.67 (+3.12%)
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes

Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive...

BMY : 60.49 (-0.49%)
XLRN : 101.67 (+3.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade XLRN with:

Business Summary

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 100.56
1st Resistance Point 99.58
Last Price 101.63
1st Support Level 97.19
2nd Support Level 95.78

See More

52-Week High 108.50
Last Price 101.63
Fibonacci 61.8% 81.19
Fibonacci 50% 72.75
Fibonacci 38.2% 64.32
52-Week Low 37.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar